Our Mission

PROVIDING A SOLUTION TO THE WORLWIDE KIDNEY SHORTAGE

Learn more

BREONICS’ Exsanguinous Metabolic Support (EMS) technology radically broadens the criteria for kidney donors to include the huge cohort of patients that die every year and are not considered for donation. EMS is the first and only technology that can overcome the technical barriers that limit access to these potential donors and will more than double the number of transplantable kidneys worldwide.

 
Learn more

Contact Us about Investor Relations.

Learn more

NEWS

News
Presentations
Technology Awards
The Potential to Regenerate Ischemically Damaged Renal Allografts
The Potential to Regenerate Ischemically Damaged Renal Allografts
International Transplant Congress: Berlin, Germany

Oral presentations: Tissue Engineering for Ex Vivo Repair of Ischemically Damaged Tubule Epithelium Potential of Tissue Engineering an Allograft into a functional Autograft.

American Society for Artificial Internal Organs: San Francisco, CA

Oral presentation: Bioengineering the Vasculature of Renal Allografts to Prevent Immune Activation: “Immunocloaking”

American Transplant Congress: Boston, Mass.

Oral presentation: Prognostic Testing of Human Cadaveric Renal Allografts Pre-transplant

International Meeting On Ischemia Reperfusion Injuries in Transplantation: Poitiers, France

Oral presentations: Tissue Engineering for Ex Vivo Repair

BREONICS, INC. prevails over Vitrolife in European Patent Opposition

BREONICS, INC. prevails over Vitrolife in European Patent Opposition

BREONICS announces the award of a NIH $2.9 Million

Albany, New York (September 01, 2010) BREONICS, INC., announced today that it has been awarded a $2.9 million research grant from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK).

Perspectives

 

“This opens the door to a future in which organs could be resuscitated from severe warm ischemia, repaired and tested for viability. Treatment by either gene transfer technology with subsequent protein expression or pretransplant immunomodulation would be revolutionary”

— Jamieson RW and Friend PJ

Transpl Reviews 2006; 20: 172-178

“Finally, a technology that causes the current paradigm to shift where the supply of kidneys could meet the demand”

— QProfessor Gauke Koostra, M.d., Ph. D.

Maastricht University, The Netherlands

Articles in Print
Related Links